Top Takeaway From ICAAC 2012: More Good News on Dolutegravir

Dr. Paul Sax reviews data from the SINGLE trial presented at ICAAC 2012 on the benefits of dolutegravir/abacavir/lamivudine vs tenofovir/emtricitabine/efavirenz.

Source: Medscape HIV AIDS Podcast - October 19, 2012 Category: HIV AIDS Authors: Medscape Source Type: podcasts